Ophthotech Corporation Initiates First Of Several Expansion Studies To Further Evaluate Fovista® (Anti-PDGF) Therapy In Patients With Wet Age-Related Macular Degeneration

NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation announced today the initiation of the first of several planned expansion trials, in addition to the ongoing Fovista® combination therapy Phase 3 clinical program. These expansion trials will investigate the potential role of Fovista® combination therapy in reducing sub-retinal fibrosis, addressing sub-optimal treatment response and reducing treatment burden in wet age-related macular degeneration (AMD) patients receiving anti-vascular endothelial growth factor (anti-VEGF) monotherapy. The first expansion trial is a Phase 2a open-label study investigating the potential role of anti-platelet derived growth factor (anti-PDGF) therapy in combination with anti-VEGF therapy in reducing sub-retinal fibrosis in wet AMD patients.

Help employers find you! Check out all the jobs and post your resume.